GSA Capital Partners LLP Sells 249,100 Shares of Amarin Co. plc (AMRN)

GSA Capital Partners LLP trimmed its holdings in Amarin Co. plc (NASDAQ:AMRN) by 72.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 93,700 shares of the biopharmaceutical company’s stock after selling 249,100 shares during the period. GSA Capital Partners LLP’s holdings in Amarin were worth $328,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in AMRN. Alkeon Capital Management LLC bought a new position in shares of Amarin during the third quarter valued at about $7,875,000. University of Notre Dame DU Lac bought a new position in shares of Amarin during the third quarter valued at about $2,814,000. JPMorgan Chase & Co. lifted its position in shares of Amarin by 681.5% during the second quarter. JPMorgan Chase & Co. now owns 278,134 shares of the biopharmaceutical company’s stock valued at $1,121,000 after purchasing an additional 242,544 shares in the last quarter. Intrinsic Edge Capital Management LLC bought a new position in shares of Amarin during the second quarter valued at about $725,000. Finally, Neuberger Berman Group LLC bought a new position in shares of Amarin during the third quarter valued at about $350,000. 40.12% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms recently weighed in on AMRN. Cantor Fitzgerald set a $10.00 price target on shares of Amarin and gave the company a “buy” rating in a research report on Thursday, January 4th. Zacks Investment Research raised shares of Amarin from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. BidaskClub raised shares of Amarin from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. Finally, ValuEngine raised shares of Amarin from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $7.75.

Amarin Co. plc (NASDAQ:AMRN) opened at $4.28 on Tuesday. The company has a current ratio of 1.63, a quick ratio of 1.32 and a debt-to-equity ratio of -1.48. Amarin Co. plc has a 12-month low of $2.81 and a 12-month high of $4.47. The firm has a market cap of $1,160.00, a PE ratio of -15.85 and a beta of 0.62.

Amarin (NASDAQ:AMRN) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $47.10 million for the quarter, compared to the consensus estimate of $45.85 million. The firm’s revenue for the quarter was up 45.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.08) earnings per share. research analysts predict that Amarin Co. plc will post -0.22 EPS for the current fiscal year.

In other Amarin news, insider Steven B. Ketchum sold 128,257 shares of Amarin stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $4.25, for a total value of $545,092.25. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider John F. Thero acquired 10,000 shares of the stock in a transaction on Thursday, November 30th. The stock was bought at an average cost of $3.24 per share, for a total transaction of $32,400.00. The disclosure for this purchase can be found here. Insiders own 3.72% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.com-unik.info/2018/01/09/gsa-capital-partners-llp-sells-249100-shares-of-amarin-co-plc-amrn.html.

Amarin Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Want to see what other hedge funds are holding AMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amarin Co. plc (NASDAQ:AMRN).

Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit